Published online May 26, 2022. doi: 10.4252/wjsc.v14.i5.362
Peer-review started: December 13, 2021
First decision: March 13, 2022
Revised: March 15, 2022
Accepted: April 27, 2022
Article in press: April 27, 2022
Published online: May 26, 2022
Processing time: 163 Days and 22.7 Hours
Pharmacological inhibitors of glutathione synthesis and circulation, such as buthionine-sulfoximine, inhibit glutathione metabolism. These drugs decrease the aggressiveness of pancreatic cancer, inhibit tumor stem cell survival, and reduce chemotherapy resistance. Nevertheless, buthionine-sulfoximine also decreases the content of glutathione in normal cells, disrupts the balance between reactive oxygen species and glutathione, and eventually induces cell apoptosis. Pancreatic cancer is usually diagnosed at an advanced stage and has a poor prognosis. Consequently, the use of biomarkers to screen high-risk patients can be an effective method.
Core Tip: To reduce side effects, pharmacological inhibitors of glutathione synthesis and circulation, such as buthionine-sulfoximine and 6-aminonicotinamide, can be assessed by in vivo models of pancreatic cancer. Evaluating the impact of different organs on metabolic processes and the invasiveness of cancer stem cells may provide new avenues for therapeutics targeting tumor metabolism.
